417 results on '"Tailleux, Anne"'
Search Results
2. Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis
3. Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis
4. Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption
5. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
6. Corrigendum to “Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis” [Mol Metab 69 (2023) 1–13]
7. The hepatic compensatory response to elevated systemic sulfide promotes diabetes
8. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
9. NASH-related increases in plasma bile acid levels depend on insulin resistance
10. Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes
11. Sirt6 deletion in bone marrow-derived cells increases atherosclerosis – Central role of macrophage scavenger receptor 1
12. Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model
13. Hepatic PPARα is critical in the metabolic adaptation to sepsis
14. Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke Patients.
15. Multi-Omics Data Integration Reveals Sex-Dependent Hippocampal Programming by Maternal High-Fat Diet during Lactation in Adult Mouse Offspring
16. MPO is partially associated with neutrophil deleterious effect in acute cerebral ischemia
17. Discovery, Structure–Activity Relationships, and In Vivo Activity of Dihydropyridone Agonists of the Bile Acid Receptor TGR5
18. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
19. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase
20. Deletion of the nuclear receptor RORα in macrophages does not modify the development of obesity, insulin resistance and NASH
21. The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids
22. Reduction of Atherosclerosis in Apolipoprotein E Knockout Mice by Activation of the Retinoid X Receptor
23. Analysis of the association of MPO and MMP-9 with stroke severity and outcome: Cohort study
24. The intestinal immune barrier is associated with bile acid pool modifications in mice suffering from non-alcoholic steatohepatitis
25. Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis
26. Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass
27. Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1
28. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?
29. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity
30. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
31. Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly
32. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction
33. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
34. Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis
35. Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation
36. Normal HDL–apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy
37. [State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)]
38. Enterohepatic, gluco-metabolic, and gut microbial characterization of individuals with bile acid malabsorption
39. Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
40. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism.
41. Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice
42. Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits
43. Roles of PPARs in NAFLD: Potential therapeutic targets
44. Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism
45. Referee report. For: Glucose induced ApoB100/ApoAI ratio changes in cultured HepG2 cells in vitro [version 2; peer review: 1 approved with reservations, 1 not approved]
46. PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH
47. p16INK4a deficiency promotes IL-4–induced polarization and inhibits proinflammatory signaling in macrophages
48. Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology
49. Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model
50. Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.